{"denoms":[{"counts":[{"groupId":"BG000","value":"198"},{"groupId":"BG001","value":"197"},{"groupId":"BG002","value":"395"}],"units":"Participants"}],"groups":[{"description":"Participants with multiple myeloma received a single dose of bortezomib 1.3 milligrams per square meter (mg/m\\^2) as subcutaneous (SC) injection twice weekly on Days 1, 4, 8 and 11 of Cycles 1 to 8. Lenalidomide 25 milligrams (mg) capsule were administered orally once daily from Day 1 to Day 14 of Cycles 1 to 8. Starting from Cycle 9, Lenalidomide capsules were administered orally once daily from Day 1 to Day 21 until disease progression or unacceptable toxicity during treatment phase. Dexamethasone 20 mg was administered as a single dose oral tablet on Days 1, 2, 4, 5, 8, 9, 11, 12 during Cycle 1 to 8. Participants aged greater than \\[\\>\\]75 years or underweight (body mass index \\[BMI\\] less than \\[\\<\\]18.5 kilograms per meters \\[kg/m\\^2\\]) were administered with Dexamethasone 20 mg oral tablets on Days 1, 4, 8, and 11 of each cycle. Starting from Cycle 9, Dexamethasone 40 mg was administered as a single tablet orally on Days 1, 8, 15, and 22 of each cycle until disease progression or unacceptable toxicity during treatment phase. Cycles 1 to 8 were 21 days each while Cycles 9 and beyond were 28 days each.","id":"BG000","title":"Arm A: Bortezomib-lenalidomide-dexamethasone (VRd)"},{"description":"Participants with multiple myeloma received a single dose of daratumumab 1800 mg as SC injection once every week in Cycles 1-2, every 3 weeks in Cycles 3-8, and every 4 weeks in Cycle 9 and beyond until disease progression or unacceptable toxicity. Bortezomib 1.3 mg/m\\^2 SC injection was administered twice weekly on Days 1, 4, 8 and 11 of Cycles 1 to 8. Lenalidomide 25 mg capsule was administered orally once daily from Day 1 to Day 14 of Cycles 1 to 8. Starting from Cycle 9, Lenalidomide capsules were administered orally once daily from Day 1 to Day 21 of each cycle until disease progression or unacceptable toxicity during treatment phase. Dexamethasone 20 mg was administered as a single oral tablet on Days 1, 2, 4, 5, 8, 9, 11, 12 of Cycle 1 to 8. Participants aged \\>75 years or underweight (BMI \\<18.5 kg/m\\^2) were administered with Dexamethasone 20 mg oral tablets on Days 1, 4, 8, and 11 of each cycle. Starting from Cycle 9, Dexamethasone 40 mg was administered as a single tablet orally on Days 1, 8, 15, and 22 of each cycle until disease progression or unacceptable toxicity during treatment phase. Cycles 1 to 8 were 21 days each while Cycles 9 and beyond were 28 days each.","id":"BG001","title":"Arm B: Daratumumab-bortezomib-lenalidomide-dexamethasone (D-VRd)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"31","upperLimit":"80","value":"70.0"},{"groupId":"BG001","lowerLimit":"42","upperLimit":"79","value":"70.0"},{"groupId":"BG002","lowerLimit":"31","upperLimit":"80","value":"70"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"87"},{"groupId":"BG001","value":"110"},{"groupId":"BG002","value":"197"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"111"},{"groupId":"BG001","value":"87"},{"groupId":"BG002","value":"198"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"66"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"147"},{"groupId":"BG001","value":"154"},{"groupId":"BG002","value":"301"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"28"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"156"},{"groupId":"BG001","value":"162"},{"groupId":"BG002","value":"318"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"19"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"25"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}],"title":"Native Hawaiian or other Pacific Islander"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"29"}]}],"title":"Not reported"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}]}